GET DAILY SIGNALSHSDT: +81% Upside to $3.50 Target as Solana Treasury Play
Key Takeaways
- The central price target used here is $3.50, the arithmetic mean of the limited set of verifiable analyst targets reviewed, which range from roughly $3.00 to $4.00.
- With HSDT recently trading near $1.93, reaching $3.50 would require an upside of about 81% — a very large move.
- HSDT is no longer a conventional medical-device company; it now operates as a digital asset treasury, holding Solana (SOL) as its primary reserve asset.
- The strongest support comes from SOL price appreciation, staking yield, and institutional backing from Pantera Capital and Summer Capital.
- The biggest risks are SOL volatility, mark-to-market losses, ongoing capital raises that dilute shareholders, and the still-modest operating revenue base.
- Analyst coverage is thin and the range is wide, so the $3.50 target should be read as a rough reference point rather than a consensus.
- For more detail on Major News, Today's Price Move, the Forecast, and Earnings, visit Tickeron's dedicated HSDT pages.
Analyst Price Targets and Consensus View
Solana Company (HSDT), formerly Helius Medical Technologies, Inc., is a Nasdaq-listed digital asset treasury that acquires and holds Solana (SOL) tokens. Analyst coverage is limited and dates rapidly. Among attributable targets, B. Riley initiated coverage with a Buy rating and a $3.00 target in April 2026, while at least one analyst raised a target to $4.00 in September 2026, and Zacks Research has also cited a $4.00 target.
Taking the verifiable individual targets of $3.00 and $4.00, the arithmetic mean is $3.50, which is the figure used throughout this article. Third-party platforms differ: Yahoo Finance lists a one-year target estimate near $3.50, while some aggregators display a consensus closer to $4.00. Because coverage is sparse and the range is wide relative to the share price, this should be treated as a directional reference point, not a firm consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With the stock recently trading near $1.93 and a 52-week range of roughly $1.185 to $5.77, a move to $3.50 implies an upside of about 81% — a very large move by any standard. The path hinges less on traditional earnings and more on the value of the company's SOL holdings, which are marked to market each reporting period.
As of late 2025, the company reported about $124 million in cash and roughly $350 million in digital assets at fair value. It holds over 2.3 million SOL tokens and earns a native staking yield of roughly 7%. Because the share price can trade at a discount or premium to the net asset value of its crypto holdings, sentiment toward Solana itself is the dominant variable.
Factors That Could Support a Move Higher
- SOL price appreciation: As a treasury company, HSDT's underlying value rises directly when Solana's token appreciates.
- Staking yield: A ~7% native staking yield, with rewards restaked, can compound SOL holdings per share over time.
- Institutional backing: Partnerships with Pantera Capital and Summer Capital, plus custody through Coinbase, BitGo, and Anchorage Digital, add credibility and execution capacity.
- Capital-return initiatives: A board-approved buyback program of up to $100 million signals management confidence.
- Solana ecosystem growth: Rising transaction volume, decentralized exchange activity, and stablecoin adoption on Solana support the treasury thesis.
Key Risks That Could Limit Upside
- SOL volatility: A 32% drop in SOL in one quarter previously produced large unrealized losses, directly pressuring the stock.
- Dilution: The company has repeatedly raised capital, including an $8 million registered direct offering at $2.60 per share and a $250 million shelf, which can dilute existing shareholders.
- Thin operating revenue: Staking revenue remains modest (about $2.5 million in a recent quarter), and net losses persist.
- Regulatory uncertainty: The crypto and digital-asset regulatory landscape remains fluid.
- Concentration: The entire investment thesis rests on a single digital asset, Solana, creating concentrated exposure.
Technical Levels and Market Structure
The stock's 52-week range of roughly $1.185 to $5.77 frames the technical picture. The $1.19 area represents a notable support level near the recent lows, while $3.50 sits well above the current price and below the prior high. The $3.00 level, where B. Riley's target sits, may act as a psychological milestone on any sustained advance. A return toward $5.77 would require a meaningful re-rating driven by renewed crypto momentum. From what I see, monitoring these levels alongside SOL price action is important because it highlights the crypto-driven nature of the moves.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though the specific horizon is rarely disclosed for HSDT and coverage is limited. Investors should monitor Solana's spot price, quarterly SOL-per-share disclosure, staking yield, capital-raising activity and its dilutive effect, and regulatory developments affecting digital-asset treasuries. The legacy medical-device operations, while now secondary, remain a secondary swing factor if monetized or divested. I’m watching this closely as the crypto correlation dominates the outlook.
Final Assessment
The $3.50 target represents the arithmetic mean of a small set of analyst targets ranging from $3.00 to $4.00, and it implies an upside of roughly 81% from recent levels near $1.93. The thesis is unusual: HSDT is now a Solana treasury vehicle whose value tracks the crypto market rather than a conventional earnings model. Support comes from SOL appreciation, staking yield, and institutional partners, while the principal obstacles are SOL volatility, persistent dilution, and thin operating revenue. Because coverage is sparse and the target range is wide, the $3.50 figure is best understood as a rough reference point. Investors should watch SOL's price, SOL-per-share metrics, and any further capital raises before drawing conclusions.
Using Tickeron AI Tools in My Research
In my own analysis workflow, Tickeron’s AI Daily Buy/Sell Signals have proven useful for tracking sentiment-driven names like HSDT. The platform applies AI to monitor technical shifts and market conditions across thousands of stocks and ETFs, helping surface potential entry or exit points that complement fundamental review. I find it efficient for volatile tickers where manual screening can miss subtle changes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for HSDT turns negative, indicating new downward trend
HSDT saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 75 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
HSDT moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HSDT crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HSDT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for HSDT entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where HSDT advanced for three days, in 171 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
HSDT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. HSDT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.688) is normal, around the industry mean (2.412). P/E Ratio (0.010) is within average values for comparable stocks, (-2.386). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.319). Dividend Yield (0.000) settles around the average of (0.270) among similar stocks. P/S Ratio (11.574) is also within normal values, averaging (15.694).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HSDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical technology company focused on neurological wellness
Industry InvestmentManagers
Advertisement